Aravax

Email: [email protected]
Phone: +61 (0)3 9657 0700
Website: https://www.aravax.com.au/
Membership category: Corporate

Magdalen Centre, 1 Robert Robinson Avenue, Oxford, Oxfordshire, OX4 4GA, United Kingdom

Aravax at a glance

Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation specific immunotherapies which are safe, effective and convenient.

About Aravax

Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation specific immunotherapies which are safe, effective and convenient. Aravax applies proprietary technology and know-how to design highly targeted immunotherapies, which reset the immune system to tolerate a specific allergen without evoking allergic reactions during treatment. The lead product, PVX108, is being developed for the treatment of peanut allergy.

Founded in 2015 based on technology from Alfred Health and Monash University, Aravax is a private company headquartered in Melbourne with an office in the Oxford Science Park. Its investors include Brandon Capital, Tenmile, Novartis Venture Fund, Breakthrough Victoria, Uniseed, UniSuper and Agati Capital.

For more information visit: www.aravax.com.au

Articles Aravax has contributed to

14 November 2024

Aravax establishes pharmaceutical development base on the Oxford Science Park

Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe, convenient, and precisely targeted, today announces it has established a UK subsidiary, based on the Oxford Science Park, as the company continues its development into an international leader in food allergies.

Member news